News AZ backs up threat of manufacturing shift from Europe AstraZeneca has said it is considering a shift in the production of some medicines from Europe to the US in order to sidestep potential tariffs.
News AbbVie makes its tariffs-driven investment play AbbVie has become the latest pharma group to make a big capital investment announcement in the US and court favour with the Trump administration.
News MSD has gauged its financial hit from Trump tariffs MSD expects to see an additional $200m layered onto its costs this year as a result of President Trump's tariffs, ahead of any pharma-specific levy.
News Roche joins the pharma firms planning big US investments Roche will spend $50bn on manufacturing and R&D facilities in the US, with a pledge to export more medicines from the US than it imports.
News US starts the clock ticking on pharma tariffs The US has launched a national security probe into the national security implications of importing pharmaceuticals, seen as a precursor to tariffs.
News Novartis plans $23bn manufacturing, R&D spend in US Novartis has announced a massive investment in manufacturing and R&D facilities in the US so it can make "100% of its key medicines" there.